Endpoint security versus productivity in the pharmaceutical industry: a false choice?

Computing's interviews with CIOs and CISOs consistently support the view that breaches are inevitable, and it is a consistent finding in both research and the recent history of the pharmaceutical sector in the UK.
Before anyone had heard the term COVID-19, the pharmaceutical industry was already a highly attractive target for attackers. It is an industry built on huge investments in the development of specific drugs, and the intellectual property (IP) on these drugs can be worth alot. However, since the industry has been front and centre in the global battle against COVID-19, both in terms of treatments and vaccine development. This has inevitably increased its value as a target.
The results shown in this research paper are drawn from a survey covering 100 IT professionals with responsibility for security strategy or implementation in pharmaceutical companies.
Download now to learn why the pharmaceutical industry does not have to choose between the securing of endpoints and the productivity of users – and security teams.